UBS Reiterates a Buy Rating on Acadia Healthcare (ACHC) With a $45 Price Target

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. In a report released on June 23, A.J. Rice from UBS reiterated a Buy rating on Acadia Healthcare Company, Inc. (NASDAQ:ACHC) with a price target of $45.00.

The company’s fiscal Q1 2025 results showed a revenue of $770.5 million compared with $768.1 million in fiscal Q1 2024. Same facility revenue for the quarter rose 2.1% compared to Q1 2024, including a 2.2% growth in patient days. In addition, patient day growth and same facility revenue both experienced an unfavorable year-over-year impact of approximately 1.1%.

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is continuing the execution of its growth strategy, adding around 378 newly licensed beds during fiscal Q1 2025, including 288 beds from newly constructed facilities and 90 beds to existing facilities.

Acadia Healthcare Company, Inc. (NASDAQ:ACHC) provides behavioral healthcare services across the US. It offers services to its patients in a range of settings, including specialty treatment facilities, inpatient psychiatric hospitals, outpatient clinics, and residential treatment centers.

While we acknowledge the potential of ACHC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.